DIQTA 1.0: Drug-Induced QT Prolongation Atlas

PRIMAQUINE PHOSPHATE

Classification:Moderate-DIQT concern

Severity Score:2.0

PRECAUTIONS
Potential Prolongation of QT Interval
Due to potential for QT interval prolongation, monitor ECG when using primaquine in patients with cardiac disease, long QT syndrome, a history of ventricular arrhythmias, uncorrected hypokalemia and/or hypomagnesemia, or bradycardia (<50 bpm), and during concomitant administration with QT interval prolonging agents (see PRECAUTIONS, DRUG INTERACTIONS, ADVERSE REACTIONS, and OVERDOSAGE).
[Drug Interactions]
Caution is advised if Primaquine is used concomitantly with other drugs that prolong the QT interval (see PRECAUTIONS, ADVERSE REACTIONS, and OVERDOSAGE).
OVERDOSAGE
Symptoms of overdosage of primaquine phosphate include abdominal cramps, vomiting, burning epigastric distress, central nervous system and cardiovascular disturbances, including cardiac arrhythmia and QT interval prolongation, cyanosis, methemoglobinemia, moderate leukocytosis or leukopenia, and anemia in G6PD deficient patients. The most striking symptoms are granulocytopenia and acute hemolytic anemia in sensitive persons. Acute hemolysis occurs, but patients recover completely if the dosage is discontinued.
ADVERSE REACTIONS
Cardiac: Cardiac Arrhythmia and QT interval prolongation (see PRECAUTIONS, OVERDOSAGE).

Current Drug

Other Drugs

QT Prolongation

24087

Other ADRs

272

38381315

Odds Ratio = 29.292

ATC Code(s):

Active Ingredient:PRIMAQUINE PHOSPHATE

Active Ingredient UNII:H0982HF78B

Drugbank ID:DB01087

PubChem Compound:4908

CTD ID:D011319

PharmGKB:PA451103

CAS Number:90-34-6

Dosage Form(s):tablet

Route(s) Of Administrator:oral

Daily Dose:

Chemical Structure:

SMILE Code:
COC1=CC(NC(C)CCCN)=C2N=CC=CC2=C1

N/A